Icon Plc $ICLR Shares Acquired by Aberdeen Group plc

Aberdeen Group plc increased its stake in Icon Plc (NASDAQ:ICLR) by 1,667.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,063 shares of the medical research company’s stock after purchasing an additional 62,325 shares during the quarter. Aberdeen Group plc owned about 0.08% of Icon worth $12,038,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ICLR. Allspring Global Investments Holdings LLC increased its position in shares of Icon by 1.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock valued at $203,800,000 after purchasing an additional 11,335 shares during the period. Legacy Wealth Asset Management LLC increased its position in shares of Icon by 4.4% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 2,587 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 110 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Icon by 43.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 1,771 shares of the medical research company’s stock valued at $323,000 after purchasing an additional 540 shares during the period. Maridea Wealth Management LLC increased its position in shares of Icon by 17.9% during the 4th quarter. Maridea Wealth Management LLC now owns 9,208 shares of the medical research company’s stock valued at $1,678,000 after purchasing an additional 1,395 shares during the period. Finally, Confluence Investment Management LLC increased its position in shares of Icon by 7.1% during the 4th quarter. Confluence Investment Management LLC now owns 5,022 shares of the medical research company’s stock valued at $915,000 after purchasing an additional 333 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ICLR shares. Jefferies Financial Group set a $135.00 price target on Icon and gave the company a “buy” rating in a research report on Monday, February 23rd. Bank of America reiterated an “underperform” rating and set a $75.00 price target on shares of Icon in a research report on Thursday, February 12th. Mizuho set a $216.00 target price on shares of Icon in a research note on Friday, January 9th. Leerink Partners reissued a “market perform” rating and set a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Finally, Robert W. Baird set a $119.00 target price on shares of Icon in a research note on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $148.80.

Icon Trading Down 2.2%

Shares of ICLR opened at $107.16 on Wednesday. The business’s 50-day moving average price is $115.97 and its 200 day moving average price is $156.93. The stock has a market capitalization of $8.65 billion, a P/E ratio of 14.50, a P/E/G ratio of 2.89 and a beta of 1.28. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.